

## **Oxford-Harrington Rare Disease Scholar Award**

### **Program Policies**

The Oxford-Harrington Rare Disease Scholar Award is a grant provided via the Oxford-Harrington Rare Disease Centre (OHC) to advance promising discoveries out of academic labs and into the clinic.

This grant is administered by the Oxford-Harrington Rare Disease Centre, a charitable new medicine development initiative of the University of Oxford and Harrington Discovery Institute at University Hospitals Health System in Cleveland, Ohio. The UK granting organisation is Fund for Cures UK, Ltd., with registration number 1185863.

### **Sponsoring Institution Requirements**

Investigators may apply from accredited academic medical centres, research institutions or universities in the United Kingdom, United States, United States territories, and Canada. Applications must be written in English. The sponsoring institution must:

- Ensure the necessary facilities and infrastructure are in place to execute the planned research project in compliance with all applicable legal and regulatory requirements and ethical standards governing research in the US, UK, and/or Canada, respectively
- Accept the award conditions, including the Budget Use of Funds and provide governance over fund expenditures
- Execute an agreement containing mutually agreeable terms and conditions.

### **Confidentiality**

Non-public applicant information is kept confidential and limited in distribution to the reviewers and the OHC administrative team, except as may otherwise be required by law. For those selected as Oxford-Harrington Rare Disease Scholars, OHC will use at its sole discretion the Scholar's name, institution, and project title on websites and to announce the award. Any additional information can be used with the Scholar's written approval.

Applicants acknowledge that the University of Oxford, University Hospitals Health System, and/or their respective affiliates may conduct research that is related to, or competitive with, proposals submitted by applicants, but Oxford and University Hospitals commit not to use confidential information submitted by applicants in Oxford or University Hospitals research.

### **Oxford-Harrington Scholar Review Panel**

The review panel consists of academic science subject matter experts and industry science professionals with expertise in drug development and commercialisation. Proposals of interest include discoveries demonstrating rigorous science, innovation, and potential for clinical impact. Projects with novel,

validated targets are of particular interest. The current focus areas of the OHC are neurological disorders, developmental and metabolic disorders, and rare cancers. Any therapeutic modality will be considered.

### **Comments from Review Committee**

Pending how far an application advances in the review process, OHC may be able to provide reviewers' comments or feedback to help applicants strengthen their proposals for future submission.

### **Use of Funds**

- **General:** Funds can be applied to direct costs that are project expenses only (no institution overhead or indirect costs). No more than £10,000 (UK) / USD\$10,000 (US and CA) of the total grant can be used for capital expenditures or equipment.
- **Salary:** The PI's salary is limited to 10% of the total award amount, and none of the funds may be used for student stipends. Note: If the award is to be used for a post-doc salary, the post-doc must be identified and in place at the start of the project term. Please identify post-doc in your budget if funds are allocated to their salary.
- **Travel:** The award may not be used for travel costs.
- With the agreement of OHC and the Sponsoring Institution, funds may be directly expended by OHC on behalf of the Sponsoring Institution.

### **Intellectual Property Guidelines**

Neither the University of Oxford nor University Hospitals through Harrington Discovery Institute or Fund for Cures UK, Ltd. claim any rights whatsoever to patents, copyrights, or trademarks to intellectual property (IP) created as a result of work sponsored by an initial OHC grant.

On all aspects of Intellectual Property, Principal Investigators are encouraged to confer with their technology transfer office and/or office of sponsored programs for guidance. Oxford-Harrington Rare Disease Scholars may seek input on patent protection from their Harrington Therapeutics Development Center advisors, who also claim no rights whatsoever to IP.

Awardees should take measures to ensure protection of any Intellectual Property in accord with national, regional, and local laws and institutional requirements.

### **Scientific Reporting & Review of Progress**

A written progress report must be submitted annually during the term of the grant. These annual reports shall contain a general update regarding the project, and any other information specified by OHC from time to time.

### **Changes to Project**

A significant change in the project scope of work after a grant agreement is executed should be discussed with the Oxford-Harrington Rare Disease Centre and Harrington Discovery Institute's Vice President of Therapeutics Development.

With permission, awards may be transferred to another institution that agrees to assume the Policies and Terms & Conditions of the agreement. Permission to transfer the award to another institution must be obtained in writing from the Oxford-Harrington Rare Disease Centre, Harrington Discovery Institute's Vice President of Therapeutics Development, and the institution originally awarded the grant.

### **Compliance & Administrative Matters**

Awards are managed through the Oxford-Harrington Rare Disease Centre to assure compliance with program and administrative policies.

The Principal Investigator and their institution are solely responsible for execution of the project, including compliance with all relevant national, regional, and local laws and guidelines.

OHC reserves the right to refine and amend policies from time to time.

### **Questions**

Questions should be directed to: [Questions@HarringtonDiscovery.org](mailto:Questions@HarringtonDiscovery.org).